Dr. Younes Discusses the Future of CAR T-Cell Therapy

Video

Anas Younes, MD, chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.

Anas Younes, MD, chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.

There is currently a CAR T cell product approved for acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), but the next disease that might benefit is multiple myeloma, says Younes. There are 2 phase I trials that were reported at the 2017 ASH Annual Meeting that showed improved response rates for patients with multiple myeloma. The number of patients investigated was small but there was a 90% response rate with a high complete response rate, explains Younes. With all these CAR T-cell therapies, the length of follow-up is short but the response rates throughout the diseases are exciting.

For example, in a dose escalation study for patients with heavily pretreated relapsed/refractory multiple myeloma, the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma. Additionally, there was a 94% objective response rate, which consisted of a very good partial response or better for 89% of patients. After 40 weeks of follow-up, the median progression-free survival (PFS) had not yet been reached, and the 9-month PFS rate was 71%. Regarding safety, the treatment was generally well tolerated.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.